DHR vs REPL · P/E 39, rev $24.57B vs $825.7M cap
Danaher Corporation (DHR) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Danaher Corporation (DHR) is a diagnostics & research company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported DHR revenue for 2025-12-31 was $24.57B. Net income was $3.61B. Revenue was up 2.9% from 2024-12-31 to 2025-12-31. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
REPL does not have a complete income-statement cache yet.
DHR currently screens at market cap $144.18B and trailing P/E 39.0. REPL currently screens at market cap $825.7M.
Not investment advice. Open the DHR and REPL stock pages for the full models.
Not investment advice.